The lowered price target from $10 to $9 by CIBC analyst Oscar Cabrera may have a neutral short-term impact on HBM's stock price. While the Outperformer rating is maintained, the reduced price target may cause some investors to reevaluate their positions, but the overall positive outlook remains.